Abstract
Forty-nine patients with Hodgkin's disease who relapsed after a first complete remission of more than 12 months following primary chemotherapy were treated with salvage therapy regimens. A total of 41 patients (84%) achieved complete remission. In particular, complete response was documented in 17 of 19 patients re-treated with the same initial drug combination. The five-year freedom from progression, relapse-free and overall survivals were 51%, 57% and 65%, respectively. In our experience, consolidation radiotherapy following drug-induced remission failed to improve the five-year relapse-free survival. Present findings indicate that about half of patients relapsing after a disease-free interval exceeding 12 months can remain alive and disease-free 5 years after starting salvage chemotherapy.
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bleomycin / administration & dosage
-
Dacarbazine / administration & dosage
-
Doxorubicin / administration & dosage
-
Etoposide / administration & dosage
-
Female
-
Hodgkin Disease / drug therapy*
-
Hodgkin Disease / mortality
-
Hodgkin Disease / pathology
-
Humans
-
Lomustine / administration & dosage
-
Male
-
Mechlorethamine / administration & dosage
-
Middle Aged
-
Prednimustine / administration & dosage
-
Prednisone / administration & dosage
-
Procarbazine / administration & dosage
-
Recurrence
-
Vinblastine
-
Vincristine / administration & dosage
Substances
-
Bleomycin
-
Procarbazine
-
Mechlorethamine
-
Vincristine
-
Vinblastine
-
Etoposide
-
Lomustine
-
Dacarbazine
-
Doxorubicin
-
Prednimustine
-
Prednisone
Supplementary concepts
-
ABVD protocol
-
CEP protocol
-
MOPP protocol